In addition to dopaminergic neuron loss, it is clear that Parkinson disease includes other pathological changes, including loss of additional neuronal populations. As a means of addressing multiple pathological changes with a single therapeutically‐relevant approach, we employed delayed transplantation of a unique class of astrocytes, GDAs^BMP, that are generated in vitro by directed differentiation of glial precursors. GDAs^BMP produce multiple agents of interest as treatments for PD and other neurodegenerative disorders, including BDNF, GDNF, neurturin and IGF1. GDAs^BMP also exhibit increased levels of antioxidant pathway components, including levels of NADPH and glutathione. Delayed GDA^BMP transplantation into the 6‐hydroxydopamine lesioned rat striatum restored tyrosine hydroxylase expression and promoted behavioral recovery. GDA^BMP transplantation also rescued pathological changes not prevented in other studies, such as the rescue of parvalbumin⁺ GABAergic interneurons. Consistent with expression of the synaptic modulatory proteins thrombospondin‐1 and 2 by GDAs^BMP, increased expression of the synaptic protein synaptophysin was also observed. Thus, GDAs^BMP offer a multimodal support cell therapy that provides multiple benefits without requiring prior genetic manipulation.